MAPK8 and tuberculosis: Any combination therapy regimens involving JNK inhibitors should only be considered during the later stages of anti-TB treatment, within a narrow treatment window, and should be accompanied by stringent monitoring of pathway inhibition, immune dynamics and drug concentrations.